Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 6/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 3/20 | 0.35 |
| ▸ | RXRB | P28702 | 3/20 | 0.35 |
| ▸ | RXRG | P48443 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | MPL | P40238 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12538599 | 0.87 | CTSS (0.49) | TRPV3KDM1ATDP1CTSSMAOB | |
| SCHEMBL12538464 | 0.86 | TRPV3 (0.45) | TRPV3KIF11MAOB | |
| SCHEMBL12537708 | 0.79 | TRPV3 (0.40) | TRPV3KDM1AMAOBKMO | |
| SCHEMBL12537989 | 0.76 | TRPV3 (0.50) | TRPV3 | |
| SCHEMBL12538116 | 0.75 | RAB9A (0.40) | TRPV3MAOB | |
| SCHEMBL12537997 | 0.73 | KMO (0.46) | TRPV3MAOBKMO | |
| SCHEMBL12538467 | 0.73 | CTSS (0.43) | TRPV3KDM1ARXRARXRBRXRG | |
| SCHEMBL12538147 | 0.73 | TRPV3 (0.46) | TRPV3MAOB | |
| SCHEMBL12538500 | 0.72 | TRPV3 (0.43) | TRPV3KMO | |
| SCHEMBL12538423 | 0.72 | KMO (0.44) | TRPV3MAOBKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012651-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20120245124-A1 | TRPV3 Modulators | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2012129491-A1 | TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245124-A1 | TRPV3 Modulators | TRPV3, TRPV2, TRPV1 | TRPV3 1/4885KDM1A 3250/4885RXRA 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.